The latest Investing Matters Podcast episode featuring Jeremy Skillington, CEO of Poolbeg Pharma has just been released. Listen here.
That London address looks interesting - https://www.scalespace.co.uk/
Thanks Poirot!
Presumably this would help with clinical trials in the States - am I right in thinking Al has previously mentioned this?
@scaredey - if you control+f "scientific advisory" in the latest annual report it only comes up 5 times: once in relation to governance, the other four in relation to the former director who left the board to chair the scientific advisory board.
Which would support your point that If the SAB barely feature in the annual report and have a largely backroom oversight function, it would make sense to take them off the primary landing page for 'people' in a website reorganisation.
No just their names are off the website - I said 'make of that what you will' because I have no idea what, if anything, that means.
I only noticed because someone flagged the site had been updated and put the archived version side by side, so I had a little look.
They've updated the site generally so perhaps they have just consolidated content - I wouldn't infer any conclusions from it!
"SAB story and prior to that Senior Scientific Advisory had gone all came from Benbenbenben. No proof otherwise. Why would he do that?"
That's not true - I merely pointed out their names had been taken off the website, which could have been for any number of reasons and I didn't suggest any!
So has the entire scientific advisory board - take from that what you will
Moderna aren't a major player?
It means there may be news on the horizon from Medusa19 and that if you have a contact there (as some have professed previously on this board) they will confirm it.
HUA inbound then?
Good spot - looks like trade press as the 'request a quote' email goes to Avacta and the 'about' section says the following:
"LabMedica International meets the need for the international dissemination of the latest techniques and applications in the clinical laboratory field worldwide. Editorial content includes up-to-date news and articles on: Clinical Applications, Scientific Advances, New Products, Technical Literature, and International Events that are of interest to clinical laboratory specialists worldwide. Subjects covered in every issue include: Clinical Chemistry, Immunology, Microbiology, Hematology, Blood-Bank, and Biomedical Research.
Circulation Information: Who Qualifies?
LabMedica International is mailed free-of-charge to qualified professionals in hospital and clinical laboratories worldwide (outside the USA and Canada). Circulation includes laboratory directors, clinical chemists, other clinical laboratory specialists, and technologists in these laboratories, as well leading distributors and dealers in the field. To qualify, readers in the above categories must request the publication in writing - by mail, fax or through email.
Publisher
Globetech Media is world leader in controlled-circulation international biomedical communications. Current Globetech publications and websites include: HospiMedica International, HospiMedica en Espanol, Medical Imaging International, Lab Medica International, Lab Medica en Espanol, Biotech News International, hospimedica.com, labmedica.com, medimaging.net as well as corresponding websites in various languages."
There's then contacts for the publication in multiple European countries, so presumably it's not just in Spanish.
Yeah he says he's speaking to management shortly and will report back tomorrow afternoon, which I imagine will be quite interesting.
The 1hr chart on IG suggests 1.5m sold between 9-10am and a gap down in the price, which suggests to me someone bigger than your regular PI dumped a load of shares (maybe these were worked through between 8-9am IDK).
Agree the volume is on the lower side of its average.
Ray, suspect you’ll need top-line data before any really press interest kicks off - trials start all the time.
Noteworthy they highlight the research centres as being led by ‘oncology opinion formers’ though; if this works as expected they won’t keep quiet for long.
Good luck to all the patients in the trial - hopefully the beginning of a major breakthrough against this terrible disease.
Someone said the other day that Avacta were shipping in pallets of 14,000 units to volume customers and below that Calibre would be the distributor. Presumably then, Calibre receives shipments in lots of 14,000.
Not that is gets you far as its pure speculation, but you can try and work out some rough numbers from that:
It's been 6 weeks since Calibre were engaged and manufacturing is scaling up, initially to 5 million p/m, but over several months:
If GAD initially produce one pallet (14k) a day, 5 days a week - 420,000 units
If GAD initially produce one pallet (14k) a day, 5 days a week for the first month, and two pallets a day for the second month (2 weeks) as they scale up - 560,000
I imagine volumes would be higher, but to me, these feel like the right sort of numbers at this stage
etc
Could also just be spread-betting companies or any number of other reasons.
That said, someone pointed out Abingdon was up 10% yesterday and wondered if it’s connected. Little point speculating but..
No worries - was reading about it the other week as was thinking the same and together, we can make this board less ****!
Urbansea: because Doxorubicin is off-patent, incredibly toxic, yet very widely used as a front line treatment across a wide range of cancers - so much so it's on the WHO list of essential medicines.
According to this paper it's the sixth most commonly used drug - https://www.researchgate.net/figure/Anticancer-drugs-used-in-various-cancers-n-200-Cyclophosphamide-was-the-most_fig1_322692836
However, Doxorubicin is part of the Anthracycline family of chemotherapies, which according to good old Wikipedia are "among the most effective anticancer treatments ever developed and are effective against more types of cancer than any other class of chemotherapeutic agents".
Indeed, this paper is titled: "The anthracyclines: will we ever find a better doxorubicin?".
https://pubmed.ncbi.nlm.nih.gov/1462166/
If you look at the other front-line chemotherapies, many of them are also Anthracycline's (look for 'rubicin' at the end of the name) - all of which have the same severe cardio toxicity, amongst other serious side effects.
Therefore, any improvement in Doxorubicin's safety profile would not only displace the existing market for Doxorubicin, but also for many of the other Anthracycline's in use.
Additionally, given the reputation of Doxorubicin, any safety improvement would attract the attention of the global oncology community, placing Avacta's technology in full view.
Much as the management are maligned on this board (unfairly, in my view), they are intelligent people who think strategically - Doxorubicin its a smart first move in my view.
@A1 Invest - you state that:
"There are minimum sample sizes for the clinical data and Avacta fall short of this currently. The Spainish clinical trials used 98 positive cases whereas the essential requirement is 100 ."
Which is true, though I would add that since the Spanish trial, the device has been validated against the Delta variant using real patient samples.
Presumably - to get a statistically meaningful result - this would have involved more than one or two patient samples.
Presumably also, this data can be incorporated into the wider data set which would take us over the threshold here - I imagine they would have kept the type of PCR comparison constant for this reason, though this is speculation on my part.
Good spot Poirot!